BioAge Labs, Inc.
Financials
Valuation Metrics
BioAge Labs, Inc.'s Market Cap is $267M. At end of 2025 it was $474M. Ranked #2928 of 3,118 in US market (top 94%), #1325 of 1,474 on NASDAQ (top 90%), #236 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 89%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $267M | US#2,928/3,118 Sec#236/265 |
| Revenue | $10M | US#2,803/3,118 Sec#168/265 |
| Net Income | $-94M | US—/3,118 Sec—/265 |
| Total Assets | $397M | US#2,835/3,118 Sec#185/265 |
| Net Assets | $375M | US#2,399/3,118 Sec#139/265 |
| Employees | 61 | US#2,676/3,118 Sec#199/265 |
| Value | ||
| P/B | 0.71x | US#194/3,118 Sec#9/265 |
| P/S | 26.01x | US#2,876/3,118 Sec#151/265 |
| FCF Yield | -33.01% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -25.20% | US#2,522/3,118 Sec#105/265 |
| ROA | -23.80% | US#2,830/3,118 Sec#140/265 |
| Op. Margin | -1035.48% | US#2,805/3,118 Sec#167/265 |
| Revenue Growth | 165.67% | US#59/3,118 Sec#22/265 |
| Financial Health | ||
| Debt Ratio | 5.87% | US#47/3,118 Sec#20/265 |
| Total Debt | $3M | US#2,928/3,118 Sec#227/265 |
| FCF | $-88M | US#2,615/3,118 Sec#137/265 |
| Cash | $74M | US#2,391/3,118 Sec#197/265 |
| Current Ratio | 17.19x | US#138/3,118 Sec#35/265 |
| Performance | ||
| 1Y Return | -23.18% | US#2,489/3,118 Sec#196/265 |
| 1M Return | -12.03% | US#2,725/3,118 Sec#216/265 |
| From 52W High | -77.60% | US#3,032/3,118 Sec#249/265 |
| 1Y MDD | -80.72% | US#3,043/3,118 Sec#247/265 |
| Trading | ||
| Volume | 564,671 shares | US#1,794/3,118 Sec#177/265 |
| Trading Value | $3M | US#2,687/3,118 Sec#218/265 |
| Per Share | ||
| EPS | $-2.06 | US—/3,118 Sec—/265 |
| BPS | $8.17 | US#1,981/3,118 Sec#86/265 |
Company Info
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.